Cour Pharmaceutical Development Company, Inc.
@courpharma
First-in-class therapies designed to reprogram the immune system
ID: 2290149181
https://courpharma.com/ 13-01-2014 19:59:41
41 Tweet
178 Followers
77 Following
#ICYMI, this Genetic Engineering & Biotechnology News article by Jonathan D. Grinstein, PhD covers the closure of our $105 million Series A and our nanoparticle approach to antigen-specific immune tolerance. Check it out here: brnw.ch/21wGGN7